JP2009509692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509692A5 JP2009509692A5 JP2008533767A JP2008533767A JP2009509692A5 JP 2009509692 A5 JP2009509692 A5 JP 2009509692A5 JP 2008533767 A JP2008533767 A JP 2008533767A JP 2008533767 A JP2008533767 A JP 2008533767A JP 2009509692 A5 JP2009509692 A5 JP 2009509692A5
- Authority
- JP
- Japan
- Prior art keywords
- opioid
- active substance
- opioid antagonist
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013543 active substance Substances 0.000 claims 19
- 238000000034 method Methods 0.000 claims 15
- 239000003401 opiate antagonist Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 11
- 239000003402 opiate agonist Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000002193 Pain Diseases 0.000 claims 6
- 230000003444 anaesthetic effect Effects 0.000 claims 6
- 230000036592 analgesia Effects 0.000 claims 6
- 230000000202 analgesic effect Effects 0.000 claims 6
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 6
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 6
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 6
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 5
- 206010040030 Sensory loss Diseases 0.000 claims 5
- 230000001939 inductive effect Effects 0.000 claims 5
- AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 claims 5
- 229960004127 naloxone Drugs 0.000 claims 5
- 229960003086 naltrexone Drugs 0.000 claims 5
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6alpha-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 claims 4
- 238000012377 drug delivery Methods 0.000 claims 4
- 229960001410 hydromorphone Drugs 0.000 claims 4
- 229960005297 nalmefene Drugs 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 239000008896 Opium Substances 0.000 claims 3
- 230000003070 anti-hyperalgesia Effects 0.000 claims 3
- -1 dextromorphamide Chemical compound 0.000 claims 3
- 239000003792 electrolyte Substances 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- DKJCUVXSBOMWAV-PCWWUVHHSA-N naltrindole Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC2=C3[CH]C=CC=C3N=C25)O)CC1)O)CC1CC1 DKJCUVXSBOMWAV-PCWWUVHHSA-N 0.000 claims 3
- 229960001027 opium Drugs 0.000 claims 3
- WXOUFNFMPVMGFZ-BDQAUFNLSA-N 7-Benzylidenenaltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC(/C5=O)=C\C=2C=CC=CC=2)O)CC1)O)CC1CC1 WXOUFNFMPVMGFZ-BDQAUFNLSA-N 0.000 claims 2
- 206010002091 Anaesthesia Diseases 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 2
- STOXPPZNSYPOHZ-BQRPEJFJSA-N N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC(=C3NC=25)N=C=S)O)CC1)O)CC1CC1 Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC(=C3NC=25)N=C=S)O)CC1)O)CC1CC1 STOXPPZNSYPOHZ-BQRPEJFJSA-N 0.000 claims 2
- 108010093625 Opioid Peptides Proteins 0.000 claims 2
- 102000001490 Opioid Peptides Human genes 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 2
- 230000037005 anaesthesia Effects 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- INUCRGMCKDQKNA-CEMLEFRQSA-N cyprodime Chemical compound N1([C@@H]2CC=3C=CC=C(C=3[C@@]3([C@]2(CCC(=O)C3)OC)CC1)OC)CC1CC1 INUCRGMCKDQKNA-CEMLEFRQSA-N 0.000 claims 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 239000000568 immunological adjuvant Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- ZHVWWEYETMPAMX-PCWWUVHHSA-N naltriben Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3OC=25)O)CC1)O)CC1CC1 ZHVWWEYETMPAMX-PCWWUVHHSA-N 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 229940127240 opiate Drugs 0.000 claims 2
- 239000003399 opiate peptide Substances 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 2
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 claims 1
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 claims 1
- XUWLAGNFLUARAN-CHQNGUEUSA-N (2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-[bis(prop-2-enyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-2-methylpropanoyl]amino]-2-methylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)C(C)(C)NC(=O)C(C)(C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)N(CC=C)CC=C)C1=CC=CC=C1 XUWLAGNFLUARAN-CHQNGUEUSA-N 0.000 claims 1
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims 1
- GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 claims 1
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 claims 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- DYUTXEVRMPFGTH-UHFFFAOYSA-N 4-(2,5-dimethylphenyl)-5-methyl-1,3-thiazol-2-amine Chemical compound S1C(N)=NC(C=2C(=CC=C(C)C=2)C)=C1C DYUTXEVRMPFGTH-UHFFFAOYSA-N 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 claims 1
- 108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 claims 1
- OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 claims 1
- 108010092674 Enkephalins Proteins 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims 1
- 108700029362 N,N-diallyl-tyrosyl-alpha-aminoisobutyric acid-phenylalanyl-leucine Proteins 0.000 claims 1
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010038678 Respiratory depression Diseases 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 238000002266 amputation Methods 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 229950002213 cyclazocine Drugs 0.000 claims 1
- NLBUEDSBXVNAPB-DFQSSKMNSA-N cyclorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CC1CC1 NLBUEDSBXVNAPB-DFQSSKMNSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000001784 detoxification Methods 0.000 claims 1
- 229960004193 dextropropoxyphene Drugs 0.000 claims 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 1
- 229960003461 dezocine Drugs 0.000 claims 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 229960000920 dihydrocodeine Drugs 0.000 claims 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 1
- 229940099212 dilaudid Drugs 0.000 claims 1
- 229950002494 diprenorphine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000000256 facial nerve Anatomy 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 239000000446 fuel Substances 0.000 claims 1
- 229940050411 fumarate Drugs 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- 229960002738 hydromorphone hydrochloride Drugs 0.000 claims 1
- 230000001571 immunoadjuvant effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims 1
- 229940001447 lactate Drugs 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- 229910001416 lithium ion Inorganic materials 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 1
- 229960000365 meptazinol Drugs 0.000 claims 1
- 229910052987 metal hydride Inorganic materials 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- 229960002921 methylnaltrexone Drugs 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 1
- 229960000677 nalmefene hydrochloride Drugs 0.000 claims 1
- OHKCLOQPSLQCQR-MBPVOVBZSA-N nalmexone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(CC=C(C)C)[C@@H]3CC5=CC=C4O OHKCLOQPSLQCQR-MBPVOVBZSA-N 0.000 claims 1
- 229950008297 nalmexone Drugs 0.000 claims 1
- 229960000858 naltrexone hydrochloride Drugs 0.000 claims 1
- 229940065778 narcan Drugs 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 1
- 229960004300 nicomorphine Drugs 0.000 claims 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 1
- 229960005301 pentazocine Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 229940116238 revex Drugs 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- 239000003970 toll like receptor agonist Substances 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72213605P | 2005-09-30 | 2005-09-30 | |
PCT/US2006/038549 WO2007041544A1 (en) | 2005-09-30 | 2006-09-29 | Transdermal drug delivery systems, devices, and methods employing opioid agonist and/or opioid antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009509692A JP2009509692A (ja) | 2009-03-12 |
JP2009509692A5 true JP2009509692A5 (es) | 2009-10-15 |
Family
ID=37696075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008533767A Withdrawn JP2009509692A (ja) | 2005-09-30 | 2006-09-29 | オピオイドアゴニスト及び/又はオピオイドアンタゴニストを用いる経皮薬剤送達システム、装置及び方法 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1931421A1 (es) |
JP (1) | JP2009509692A (es) |
KR (1) | KR20080058433A (es) |
CN (2) | CN101321554A (es) |
AU (1) | AU2006299521A1 (es) |
BR (1) | BRPI0616788A2 (es) |
CA (1) | CA2622684A1 (es) |
IL (1) | IL190245A0 (es) |
RU (1) | RU2008117168A (es) |
WO (1) | WO2007041544A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100239523A1 (en) * | 2007-10-30 | 2010-09-23 | The Regents Of The University Of Colorado | Tlr modulators and methods for using the same |
US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
US8691768B2 (en) | 2008-05-01 | 2014-04-08 | The Regents Of The University Of California | Methods of determining delta opioid receptor subtypes |
WO2010110397A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人 香川大学 | マイクロニードルおよびその製造方法と金型 |
CA2841785A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 薬剤送達方法及びシステム |
WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
CN106730311B (zh) * | 2016-12-27 | 2019-10-29 | 潍坊大地医疗器械有限公司 | 经络综合治疗仪电极触头装置 |
CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
GB201704909D0 (en) * | 2017-03-28 | 2017-05-10 | Ldn Pharma Ltd | Cancer therapy |
WO2019090125A2 (en) * | 2017-11-02 | 2019-05-09 | Chrono Therapeutics Inc. | Smart abuse-deterrent transdermal drug delivery system |
JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
US11129795B2 (en) * | 2019-02-21 | 2021-09-28 | Pharmaceutical Productions, Inc. | Naloxone formulations for sublingual and/or buccal administration |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
US4722726A (en) * | 1986-02-12 | 1988-02-02 | Key Pharmaceuticals, Inc. | Method and apparatus for iontophoretic drug delivery |
US4879297A (en) * | 1987-06-01 | 1989-11-07 | Warner-Lambert Company | Fatty acids and their small chain esters as penetration enhancers in aqueous systems |
US5312326A (en) * | 1992-06-02 | 1994-05-17 | Alza Corporation | Iontophoretic drug delivery apparatus |
DE602004009449T2 (de) * | 2003-07-25 | 2008-07-24 | Euro-Celtique S.A. | Behandlung von entzug |
TW200640526A (en) * | 2005-02-24 | 2006-12-01 | Alza Corp | Transdermal electrotransport drug delivery systems with reduced abuse potential |
-
2006
- 2006-09-29 AU AU2006299521A patent/AU2006299521A1/en not_active Abandoned
- 2006-09-29 CN CNA2006800450261A patent/CN101321554A/zh active Pending
- 2006-09-29 WO PCT/US2006/038549 patent/WO2007041544A1/en active Application Filing
- 2006-09-29 CA CA002622684A patent/CA2622684A1/en not_active Abandoned
- 2006-09-29 RU RU2008117168/14A patent/RU2008117168A/ru unknown
- 2006-09-29 EP EP06816083A patent/EP1931421A1/en not_active Withdrawn
- 2006-09-29 BR BRPI0616788-8A patent/BRPI0616788A2/pt not_active Application Discontinuation
- 2006-09-29 CN CNA2006800449368A patent/CN101316623A/zh active Pending
- 2006-09-29 KR KR1020087010036A patent/KR20080058433A/ko not_active Application Discontinuation
- 2006-09-29 JP JP2008533767A patent/JP2009509692A/ja not_active Withdrawn
-
2008
- 2008-03-18 IL IL190245A patent/IL190245A0/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009509692A5 (es) | ||
RU2008117168A (ru) | Системы, устройства и способы для чрезкожной доставки лекарств, использующие опиоидный агонист и/или опиоидный антагонист | |
US5149538A (en) | Misuse-resistive transdermal opioid dosage form | |
JP2010189403A5 (es) | ||
JP2006524261A5 (es) | ||
RU98102450A (ru) | Способ эпидурального введения терапевтических соединений с поддерживаемой скоростью высвобождения, способ уменьшения угнетения дыхания | |
US20100227876A1 (en) | Methods of Reducing Side Effects of Analgesics | |
US10398690B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
JP2004512260A5 (es) | ||
CA2569742A1 (en) | Opioids for the treatment of the restless leg syndrome | |
JP2011519930A5 (es) | ||
WO2008025790A2 (en) | Use of opioid formulations in needle-less drug delivery devices | |
RU2012124063A (ru) | Лекарственная комбинация с теобромином и ее использование в лечении | |
US10226457B2 (en) | Systems and methods for treating an opioid-induced adverse pharmacodynamic response | |
EP3190890A1 (en) | Systems and methods for attenuating opioid-induced euphoria | |
MX2008004223A (es) | Sistemas, dispositivos y metodos de suministro transdermico de farmacos que emplean un agonista opioide y/o un antagonista opioide | |
KR20180074797A (ko) | 통증 치료를 위한 오피오이드 작용제 및 오피오이드 길항제의 비-경피 전달된 n-옥시드 유도체를 포함하는 남용 방지 경피 전달 장치 및 조성물 | |
JP2018534319A5 (es) | ||
US20100317682A1 (en) | Single Dosage Unit Including Opioid and Methylnaltrexone or Methylnaltrexone Salt | |
JP2005529106A5 (es) |